Moderna said on Wednesday the U.S. Food and Drug Administration has agreed to review its influenza vaccine, reversing an earlier decision to reject the application, after the company made modification...

The FDA says it will now review a new m-r-n-a flu vaccine from Moderna.

The FDA news is largely positive for MRNA stock as it positions the company’s influenza vaccine for the upcoming flu season.